Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Gonçalves

Showing results (1-10 of 180) with videos related to

Pageof 18
Sort By:
Bulletin Du Cancer|March 28, 2012
[PARP inhibitors and breast cancer: update and perspectives]Anthony Gonçalves
Bulletin Du Cancer|August 7, 2016
[Not Available]Anthony Gonçalves
Bulletin Du Cancer|March 18, 2015
[Neoadjuvant chemotherapy in triple-negative breast cancer: is there a role for platinum?]Anthony Gonçalves
Bulletin Du Cancer|July 29, 2011
[Eribulin: a new therapeutic option in intensely pretreated metastatic cancer of the breast?]Anthony Gonçalves
Bulletin Du Cancer|March 28, 2016
[Financial stress: A prognostic factor for cancer survival!]Anthony Gonçalves
Bulletin Du Cancer|May 7, 2018
[CDK4/6 inhibitors: biomarkers, mechanisms of resistance and interest of the study of the circulating tumor DNA]Anthony Gonçalves
Medecine Sciences : M/S|April 14, 2009
[Metastatic colorectal cancers and targeted therapy against EGFR]Frédéric Viret, Anthony Gonçalves
Journal of Mammary Gland Biology and Neoplasia|September 2, 2006
The ErbB2 signaling network as a target for breast cancer therapyAli Badache, Anthony Gonçalves
Bulletin Du Cancer|August 6, 2014
[Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers]Renaud Sabatier, Anthony Gonçalves
Current Oncology Reports|August 12, 2017
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1François Bertucci, Anthony Gonçalves
Pageof 18

Showing results (1-10 of 180) with videos related to

Sort By:
Pageof 18
Bulletin Du Cancer|March 28, 2012
[PARP inhibitors and breast cancer: update and perspectives]Anthony Gonçalves
Bulletin Du Cancer|August 7, 2016
[Not Available]Anthony Gonçalves
Bulletin Du Cancer|March 18, 2015
[Neoadjuvant chemotherapy in triple-negative breast cancer: is there a role for platinum?]Anthony Gonçalves
Bulletin Du Cancer|July 29, 2011
[Eribulin: a new therapeutic option in intensely pretreated metastatic cancer of the breast?]Anthony Gonçalves
Bulletin Du Cancer|March 28, 2016
[Financial stress: A prognostic factor for cancer survival!]Anthony Gonçalves
Bulletin Du Cancer|May 7, 2018
[CDK4/6 inhibitors: biomarkers, mechanisms of resistance and interest of the study of the circulating tumor DNA]Anthony Gonçalves
Medecine Sciences : M/S|April 14, 2009
[Metastatic colorectal cancers and targeted therapy against EGFR]Frédéric Viret, Anthony Gonçalves
Journal of Mammary Gland Biology and Neoplasia|September 2, 2006
The ErbB2 signaling network as a target for breast cancer therapyAli Badache, Anthony Gonçalves
Bulletin Du Cancer|August 6, 2014
[Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers]Renaud Sabatier, Anthony Gonçalves
Current Oncology Reports|August 12, 2017
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1François Bertucci, Anthony Gonçalves
Pageof 18